The rise of Viagra initially drove a boom for pharma, but recent shifts present a complicated outlook for shareholders. Off-patent competitors are eroding profits, and continued legal battles add more risk to the https://zoewjpv473043.targetblogs.com/41490798/the-blue-pill-and-big-pharma-a-risky-bet